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ABSTRACT
Childhood asthma can be a challenging condition to manage and often requires
individually tailored pharmacologic therapy in order to prevent symptom exacerbation and
subsequent hospitalizations. Many patients and their families seek guidance from primary care
providers or specialty care clinics to help in navigating appropriate medication management and
symptom control. This study aimed to identify the role of specialty care management in pediatric
asthmatics through the completion of a systematic chart review of patient records obtained from
a Minnesota-based pediatric pulmonology clinic. The methodology included a qualitative
retrospective cohort analysis which focused on patient referral source, specific treatment
interventions, and the corresponding effect on patient outcomes through the utilization of
specialty care management. The study gathered data from direct chart review as well as
statistical analysis using a paired t-test. The results indicated that the most frequent referral
source leading to specialty care consultation came from the patient’s primary care provider.
Patient medication regimens were also evaluated for the most appropriate and effective treatment
options. Lastly, the results showed a statistically significant change in asthmatic symptom
control and improved patient outcomes by incorporating specialty care management. The
findings suggested how specialty care consultation, most commonly based on a referral from a
primary care provider, may impact patient outcomes and improve overall quality of life.
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Chapter 1: Introduction
Introduction
Asthma is one of the most prevalent childhood illnesses throughout the world (Allergy &
Asthma Network, 2016; Centers for Disease Control and Prevention, 2019a; Global Initiative for
Asthma, 2019a). This chapter provides key background information about pediatric asthma, as
well as explains the research question answered by this study. The purpose of this study sought
to retrospectively analyze a specific pediatric asthma specialty care clinic in Minnesota during
January 2018 through December 2018 and identify the most common referral sources, types of
medication utilized, and subsequent patient outcomes. Chapter one illuminates the significance
of this research to the healthcare community, and explores the limitations of this study.
Background
Oxygen provides fuel for the body to perform conscious and unconscious actions that
support life. Breathing aids in the recruitment of oxygen from the environment, introducing it
into the lungs and then into the bloodstream to be distributed (Longo, Kasper, Jameson, Fauci,
Hauser, & Loscalzo, 2012). This process also assists in the excretion of waste product, carbon
dioxide, through exhalation (Emmett & Palmer, 2018). As a result, pH may be acutely regulated
with changes in breathing (Emmett & Palmer, 2018). When this process is disturbed or altered,
catastrophic and irreversible damage can occur. Asthma is a condition of the lungs that causes
bronchospasms leading to reduced airflow out of the lungs (Longo et al., 2012). Exacerbations of
asthma can result in low oxygen saturations leading to ED visits, hospitalizations, or even death
(Xhelo, 2017). The risk of exacerbation increases with poorly controlled asthma, therefore, it is
important to manage asthma appropriately.
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There are many subsets within the main diagnosis of asthma. These subsets include
exacerbating triggers as well as the classification of severity. Common triggers among pediatric
asthmatics include viral illnesses, exercise, weather, smoke exposure, allergens, and irritant
exposures (Sawicki & Haver, 2018). With the variation in triggers and types, asthma may present
differently. However, commonly associated symptoms include cough, wheeze, dyspnea, chest
tightness, or allergic symptoms (Sawicki & Haver, 2018). Depending on the incidence of
symptoms and pulmonary function testing, asthma is classified as either intermittent, mild
persistent, moderate persistent, or severe persistent. These classifications direct providers to the
appropriate treatment plan, using international recommendations (Global Initiative for Asthma,
2019a). Treatment includes a step-down approach utilizing different combinations of inhaled
corticoid steroids, leukotriene receptor antagonists, and bronchodilators (Global Initiative for
Asthma, 2019a).
In 2017, the CDC published statistics that demonstrated 8.4% of children in the United
States were diagnosed with asthma (Centers for Disease Control and Prevention, 2019a). In
Minnesota, this percentage was slightly decreased at 7.4%, with 310,955 cases (Centers for
Disease Control and Prevention, 2019b). MN Community Measurement is an organization
within the state that collects and publishes patient outcomes for different illnesses, including
asthma. According to the 2017 MN Community Measurement data, 180,043 children had
uncontrolled asthma (MN Community Measurement, 2019). In a retrospective study, it was
demonstrated that 44% of pediatric patients did not follow up with a specialty care following an
emergency department visit, opposing guidelines put forth by the American Academy of Allergy,
Asthma & Immunology (Price, Bjermer, Bergin & Martinez, 2017).
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Problem Statement
Asthma is a chronic illness that with proper medical therapy can be well-controlled.
However, asthma management may be complicated by different factors leading to poorly
controlled asthma. Poorly controlled asthma comes with an increased risk of exacerbations
resulting in clinic visits, emergency department visits, or even hospitalizations. Annually,
children requiring a trip to the emergency department is 20% (Dondi et al., 2017). Those who
have required emergency interventions are at an increased risk of developing another severe
asthma attack (Dondi et al., 2017). According to Minnesota Community Measurement, only
57.9% of pediatric asthmatics in the state are well-controlled (MN Community Measurement,
2019). Currently, there is limited research about the role of specialty management of pediatric
asthma.
Purpose
The purpose of this study sought to retrospectively analyze a specific pediatric asthma
specialty care clinic in Minnesota during January 2018 through December 2018 and identify the
most common referral sources, types of medication utilized, and subsequent patient outcomes.
This study explored the impact of specialty care in pediatric asthmatics, by looking at different
parameters following specialty care management. This was completed by analyzing different
treatment options utilized, as well as patient outcomes. New patients were reviewed to research
common trends in referral patterns. Using a retrospective analysis, this study aided in
understanding the role of pulmonary specialty care in the pediatric population with asthma in
Minnesota.
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Significance of the Problem
In the pediatric population, asthma exacerbations are one of the top causes of admissions
to the hospital and can be life-threatening (Dondi et al., 2017). The mortality rate for children
ages 0-4 years old in the United States is 1.8% and nearly doubles with ages 5-17 years old to
3.2% (Centers for Disease Control and Prevention, 2018). Due to the prevalence of hospital
admissions and emergency department visits, asthma control is critical in improving the physical
health and quality of life in pediatric patients. Asthma may be managed by a primary care
provider or by specialty care provider such as an allergist or pulmonologist. With the questions
proposed in this study, the role of specialty management will be examined. This information may
be useful for primary care providers when considering a referral. This may also be a helpful
resource for parents of children with poorly controlled asthma.
Research Questions
The intent of this research project was to analyze the following questions using an indepth chart review of pediatric patients seen at a pulmonology specialty care clinic in the
Minnesota metro from January 2018 through December 2018:
1. What were the most common referral sources leading to specialty consultation for
pediatric asthmatics management and control?
2. What was the role of specialty care management in pediatric asthma? Specifically, what
types of interventions, counseling, or treatments were offered to Minnesota patients at
this specialty care clinic from January 2018 through December 2018?
3. How did specialty care management influence or affect pediatric asthmatic outcomes?
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Limitations/Delimitations
This study was limited due to the inability to control for patient compliance with
treatment recommendations or availability of resources. Additionally, this study could not
account for the primary care management of the pediatric patients before coming into the
specialty care clinic, nor specifically, determine when a referral was discussed and the time in
which the patient chose or was able to come in for the initial assessment and how that may have
impacted outcomes. Lastly, another limitation would be the available treatment therapy
recommendations and options available during the predetermined timeframe of January 2018
through December 2018. Recently, the 2019 Global Initiative for Asthma (GINA) published new
recommendations that could be considered the most fundamental change in asthma management
in 30 years (Reddel et al., 2019). One of these new asthma management recommendations
discouraged the once-standard use of short-acting bronchodilators alone as needed, and now
advised the use of a combination inhaler with a corticosteroid and long-acting bronchodilator for
rescue inhalation (Global Institute for Asthma, 2019). As this study reviewed patient records
before this change in guidelines, the treatment strategies utilized at that time may not be what is
currently recommended for pediatric asthmatic control. As far as the delimitations of the
research, this study was confined to the analysis of chart reviews at one specific pulmonology
specialty care clinic in the Minnesota metro area. Additionally, the charts reviewed spanned from
a pre-determined time frame from January 2018 through December 2018.
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Definitions of Terms
The following important terms are defined below and should be considered throughout this
article and for the purpose of this study.
1. Asthma Control Test (ACT): A self-administered validated tool for subjectively assessing
asthma control (Liu et al., 2007).
2. Bronchodilator: A substance that relaxes contractions of the smooth muscle within the
bronchioles to improve lung ventilation (Anderson, 2002).
3. Dyspnea: A distressful sensation of uncomfortable breathing (Anderson, 2002).
4. Exacerbation: An increase in the seriousness of a disease marked by greater intensity in
patient symptoms (Anderson, 2002).
5. Forced Expiratory Volume: The volume of air that can be expelled in a set period after
full inspiration, usually set at one second (Anderson, 2002).
6. Forced Vital Capacity: The maximum volume of air that can be forcibly exhaled after full
inspiration (Anderson, 2002).
7. Inhaled Corticosteroids (ICS): An effective anti-inflammatory medication for asthma
used to increase lung function, reduce symptoms, and reduce the risk of asthma-related
hospitalizations and death (Global Initiative for Asthma, 2019).
8. Leukotriene Modifiers: Target one part of the inflammatory pathway in asthma
specifically blocking chemicals that cause the airways to tighten and narrow (Global
Initiative for Asthma, 2019).
9. Long-Acting Inhaled Beta-Agonist Bronchodilators (LABA): A scheduled inhaled
asthma medication used in conjunction with a corticosteroid to improve lung function as
well as reduce symptoms and exacerbations (Global Initiative for Asthma, 2019).
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10. Short-Acting Inhaled Beta-Agonist Bronchodilators (SABA): An inhaled asthma
medication used as needed for quick relief of asthma symptoms and bronchoconstriction
in exacerbation or preemptively for exercise-induced asthma treatment (Global Initiative
for Asthma, 2019).
11. Spirometry: Laboratory evaluation of the air capacity of the lungs (Anderson, 2002).
12. Wheezing: A high-pitched whistling sound associated with labored breathing (Anderson,
2002).
Conclusion
In summary, as asthma continues to be a prevalent and life-limiting childhood illness, it is
essential to understand how best to control this disease. This research discussed how the
incorporation of specialty care may have influenced outcomes in pediatric asthmatic
management using a statistical analysis and chart review derived from a Minnesota pediatric
pulmonology clinic. The following chapter provides a comprehensive understanding of the
asthmatic condition as well as an in-depth literature review and analysis of the current research
in asthma treatment and the specific quality measures and rankings of pediatric asthmatic
management in Minnesota.
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Chapter 2: Literature review
Introduction
"When you inhale, you are taking the strength from God. When you exhale, it represents the
service you are giving to the world (Iyengar, 2005)."
Breathing is a precious gift; it is an ability that should not be taken for granted. But what
happens when that ability is hindered, when the capacity to inhale and exhale is challenged and
limited? This chapter discussed the obstructive breathing condition of asthma and how it affects
the pediatric population. More specifically, this chapter provided an in-depth research analysis of
the current literature describing patient presentation, diagnostic criteria, treatment modalities,
and collaborative interdisciplinary care for prevention and management of pediatric asthma.
Lastly, this chapter reviewed the recent data collected in the state of Minnesota on quality
measurements of pediatric asthmatic control and how this correlated with the use of specialty
care clinic referrals to assist in the prevention, management, treatment, and overall improved
patient outcomes.
Pathophysiology
Asthma is a respiratory syndrome defined by varied airflow narrowing and obstruction
(Longo, 2012). Asthmatics are more susceptible to a wide range of triggering factors that lead to
inflammation within the airways. This perpetuates the bronchial narrowing which reduces
airflow and causes characteristic wheezing, shortness of breath, chest tightness, cough, and
dyspnea (Longo, 2012). Asthma is generally reversible through the use of bronchodilators, but in
some patients, the disease can become chronic and irreversible despite pharmacologic
intervention (Longo, 2012). An acute asthma attack or exacerbation occurs when the
environmental triggers cause the smooth muscle lining the bronchi and bronchioles to narrow
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and contract (Xhelo, 2017). Additionally, the inflammation and pulmonary hyperresponsiveness
induced by the trigger generates mucus production leading to increased breathing difficulty. As
the chest tightens, wheezing occurs as air whistles through the narrowed space. Eventually, it
becomes harder for the asthmatic to exhale producing hyperinflation and air trapping within the
lung space. The body must now work harder to maintain adequate gas exchange throughout the
bloodstream. Without proper intervention, death can occur from the lack of oxygen delivery to
essential organs such as the brain and heart (Xhelo, 2017).
Prevalence
Globally, asthma is considered one of the most common chronic diseases worldwide
(Masoli, Fabian, Holt, & Beasley, 2004). Estimations taken from the Global Initiative for
Asthma (GINA) reported over 300 million people in the world of all ages and ethnicities
currently have asthma and approximately 250,000 individuals die from the disease each year
(Masoli et al., 2004). Asthma has become more common in both children and adults around the
world in recent decades. The increase in the prevalence of asthma has been associated with an
increase in atopic sensitization and is paralleled by similar increases in other allergic disorders
such as eczema and rhinitis (Liu et al., 2007). Rates of asthma increase as communities adopt
western lifestyles and become urbanized. (Masoli et al., 2004). As the global population
increases, there is likely to be a corresponding increase in the number of asthmatics worldwide.
Estimations show that there may be an additional 100 million people afflicted with asthma by
2025 (Masoli et al., 2004). More recent literature on global prevalence of asthma has been
hindered by variations in definitions as well as method collection making accurate incidence
reporting difficult (Litonjua & Weiss, 2018).
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Furthermore, asthma is the most common chronic disease of childhood (Sawicki &
Haver, 2018). In the United States, the Center for Disease Control and Prevention (CDC)
reported the prevalence of children who have ever been diagnosed with asthma to be over nine
million, and over six million children still have the disease (Centers for Disease Control and
Prevention, 2017b). The following diagrams represented the prevalence of pediatric asthma cases
collected from the 2017 National Health Interview Survey data from national and state
surveillance systems administered by the CDC seen on the following figures. Figure 1 illustrated
the population of pediatric asthmatics broken down by age. Figure 2 separated the prevalence of
pediatric asthma by gender. Figure 3 distinguished between ethnic groups and the prevalence of
childhood asthma.

Figure 1. 2017 national current asthma prevalence categorized into childhood age groups of 0-4
years, 5-11 years, and 12-221 years (Centers for Disease Control and Prevention, 2017b).

20

Figure 2. 2017 national current asthma prevalence in pediatrics categorized into boys and girls
(Centers for Disease Control and Prevention, 2017b).
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Figure 3. 2017 national current asthma prevalence categorized by ethnicity groups of White
(non-Hispanic), Hispanic, Black (non-Hispanic), Mexican, Other (non-Hispanic), and Puerto
Rican (Centers for Disease Control and Prevention, 2017b).
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Risk Factors and Etiology
The presence of viral upper respiratory infections is the primary triggering factor for the
development of wheezing illness and acute asthma exacerbations in childhood (Gern, 2014).
During infancy, babies infected with respiratory syncytial virus (RSV) may develop mild
respiratory symptoms of which are self-limiting and without complications (Gern, 2014).
Alternatively, some infants with RSV experience more severe symptoms of cough, wheezing,
and hypoxia which are associated with an increased risk for developing asthmas later in
childhood. Exposure to severe viral infections may adversely affect long-term pulmonary
physiology and development which predisposes infants to asthma or other lung-related chronic
conditions (Gern, 2014).
Additionally, a number of prenatal and perinatal factors including maternal age greater
than 30 years, genetics, tobacco use, diet, medications (specifically acetaminophen intake),
vitamin D deficiency and absence of breastfeeding have been suggested as possible risk factors
in the development of pediatric asthma, although the collected data has not been conclusive
(Litonjua & Weiss, 2019). A strong association, however, does exist with allergic disease and the
development, severity, and persistence of asthma (Sawicki & Haver, 2018). Atopy is the genetic
predisposition to create specific IgE antibodies following exposure to allergens correlating with
airway hyperresponsiveness and is considered a prerequisite for the development of allergic
disease (Sawicki & Haver, 2018). The Epidemiology and Natural History of Asthma Outcomes
and Treatment Regimens (TENOR) study, an observational study of patients with severe or
difficult-to-treat asthma, determined that children with severe asthma tend to have marked
elevated atopy and that allergen exposure was a noted trigger for asthma symptoms for the
estimated 80% of childhood asthmatics with comorbid allergic disease (Chipps et al., 2007).
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Signs and Symptoms
Each individual with asthma is unique in his or her triggers. Common triggers include
upper respiratory infections, allergen exposure, or exercise (Miller, 2018). Other triggers include
the weather and temperature, hormonal fluctuations, medications, and emotional states (Miller,
2018). Anxiety and stress are two emotional triggers that may influence an exacerbation (Miller,
2018). For some individuals, triggers may be due to selective irritants, such as smoke exposure
or air pollution (Miller, 2018). Due to the various triggers that exacerbate asthma, symptoms
may vary from case to case.
Of pediatric asthmatics, 80% of children will become symptomatic before age five
(Sawicki & Haver, 2018). One common symptom of asthma in children is cough (Sawicki &
Haver, 2018). Without other presenting symptoms, children with asthma may be misdiagnosed
with bronchitis (Sawicki & Haver, 2018). An asthmatic cough is often a non-productive cough,
although it may be productive (Sawicki & Haver, 2018). Children may cough throughout the
day, or they may cough nocturnally as well (Sawicki & Haver, 2018). A cough may also be
seasonal, depending on the etiology of asthma. For example, if a child has allergic asthma that is
triggered by ragweed, then he or she may have a lingering cough throughout the fall. Along those
lines, a cough may follow certain triggers such as bonfires, laughing, or exercise (Sawicki &
Haver, 2018). Children with a lingering cough that lasts longer than three weeks should be
evaluated for asthma, as untreated asthma is the most common cause of chronic cough in
children under three years old (Sawicki & Haver, 2018). Other common symptoms include chest
tightness, dyspnea, and some children may have exercise limitations. Allergic symptoms may be
present if a child has an atopic etiology such as rhinitis, conjunctivitis, or eczema (Sawicki &
Haver, 2018).
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The hallmark of asthma is the presence of a wheeze. This is a musical sound heard upon
exhalation. Wheezing is often heard on physical exam through a stethoscope, although in severe
cases a wheeze may be audible without the use of a stethoscope (Sawicki & Haver, 2018).
During an asthma exacerbation, a lack of wheeze is considered an emergency, indicating
extremely reduced airways (Sawicki & Haver, 2018). For children with asthma, physical
examinations of the lungs outside of asthma exacerbation will often have normal findings
(Sawicki & Haver, 2018). However, at baseline, some children may present with decreased air
entry or wheezing, increased AP diameter, or prolonged expiratory phase on auscultation
(Sawicki & Haver, 2018). This is indicative of poorly controlled asthma. Children with an
allergic component may also present with an allergic salute or allergic shiners at baseline
(Sawicki & Haver, 2018). An allergic salute is a nasal crease formed due to repeated rubbing of
the nose, while allergic shiners are a result of venodilation beneath the eyes leading to swelling
(deShazo & Kemp, 2018). Along with allergy symptoms, eczema and nasal polyps may also be
found in children with asthma (Sawicki & Haver, 2018). An association between increased body
mass index and increased severity of asthma is present, although the causation is controversial
(Sawicki & Haver, 2018). During an exacerbation, tachypnea, hypoxia, wheezing, accessory
muscle use, retractions, and prolonged expiratory phase may be found (Sawicki & Haver, 2018).
Diagnosis
In diagnosing children with asthma, patient history and physical exam can be suggestive
of asthma. However, there are three criteria for the confirmation of an asthma diagnosis. Criteria
include variable expiratory airflow limitation, documentation of reversible obstruction, and
exclusion of differential diagnoses (Sawicki & Haver, 2018). Differential diagnoses for acute
wheezing to rule out asthma include bronchiolitis, laryngotracheobronchitis, atypical infection,
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bacterial tracheitis, foreign body aspiration, and esophageal foreign body (Sawicki & Haver,
2018). Chronic causes of wheezing can be split into anatomical and functional. Anatomical
differential diagnoses include tracheobronchomalacia, vascular compression, tracheal stenosis,
cystic lesions, tumors, lymphadenopathy, or cardiomegaly (Sawicki & Haver, 2018). Chronic
functional differential diagnoses for wheezing include gastrointestinal reflux, recurrent
aspiration, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, pulmonary edema,
bronchopulmonary dysplasia, retained foreign body, bronchiolitis obliterans, vocal cord
dysfunction, and interstitial lung disease (Sawicki & Haver, 2018).
In children over the age of five years old, spirometry is useful in the diagnosis of asthma.
Forced vital capacity (FVC) reveals the total amount of air moving out of the lungs after a forced
exhalation. Forced expiratory volume (FEV1) measures the amount of air blown out in one
second. In individuals with asthma, their FEV1 may be decreased below 80% predicted value
demonstrating an obstructive pattern consistent with asthma (Sawicki & Haver, 2018). Other
values consistent with a diagnosis of asthma include a decreased FEV1/FVC ratio below 85%
predicted value, and FEF 25-75 below 65% predicted (Sawicki & Haver, 2018). FEV1/FVC ratio
is beneficial in assessing the current impediment of air and function of the lungs, while FEV1 has
been shown to be a predictor of future exacerbations (Sawicki & Haver, 2018). Spirometry
should be repeated after bronchodilator usage. If FEV1 values increase by 12%, then there is a
significant response to albuterol. This helps diagnose asthma in individuals with normal FEV1
values (Sawicki & Haver, 2018).
Spirometry is beneficial for the diagnosis of asthma, however, this test is contraindicated
for children under the age of five. Due to this, many different diagnoses may be given for
recurrent wheezing. Reactive airway disease, wheezy bronchitis, asthmatic bronchitis, and

26
wheezing associated respiratory illness are some names used interchangeably in young children
(Sawicki & Haver, 2018). For both young children and adolescents, patient history is important
in confirming the asthma diagnosis. Taking a thorough history can help identify patterns in a
child (Townshend, Hails, & McKean, 2007). Symptom patterns may help identify triggers or
distinguish between differential diagnoses (Townshend et al., 2007). Do the symptoms occur
with illnesses, with exercise, at grandma’s house, at a certain time of the year, or during sleep are
some questions that can help narrow down triggers (Townshend et al., & McKean, 2007).
Obtaining a family history may help direct diagnosis if there is a significant history of asthma or
eczema in the family (Townshend et al., 2007).
A thorough history can also help assess the degree of illness (Townshend et al., 2007).
Some questions that may be beneficial in evaluating severity are “Is your child able to keep up
with peers, are they missing school, has your child ever been prescribed respiratory medications,
if so, have they been beneficial” (Townshend et al., 2007)? To make a diagnosis, patients may
also be trialed on asthma medications. Responsiveness to these medications can be suggestive of
asthma, specifically responsiveness to albuterol (Sawicki & Haver, 2018). Other tests may be
done to rule out differential diagnoses, such as a chest x-ray, allergy testing, sweat chloride test,
swallow study, and exhaled nitric oxide levels (Sawicki & Haver, 2018).
Once asthma has been diagnosed, the provider must categorize the severity of asthma.
Children with asthma may be diagnosed with exercise-induced, mild intermittent, mild
persistent, moderate persistent, or severe persistent. Asthma in children is categorized based on
symptom burden, short-acting beta-agonist (SABA) use, exercise limitations, lung function, and
oral steroid use, as seen in Table 1. Classifications for asthma in children under 12 years old
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remain the same as the criteria that are indicated for 12 years and older (Healthwise Staff, 2018).
Asthma classifications help direct treatment.
Table 1
Diagnostic Criteria for Children 12 Years and Older (Pollart & Elward, 2009).
Intermittent
Mild
Moderate
Severe
persistent
persistent
persistent
Symptoms
≤ 2 days per
> 2 days per
Daily
Throughout the
week
week, but not
day
daily
Nocturnal
≤ 2 times per
3 to 4 times per
> once per week, Often 7 times
symptoms
month
month
but not nightly
per week
Short-acting
≤ 2 days per
> 2 days per
Daily
Several times
beta-agonist use week
week, but not
per day
more than once
per day
Exercise
None
Minor
Some limitations Extreme
limitations
limitations
limitations
Lung function
FEV1 percent
FEV1 ≥
FEV1 60-80
FEV1 < 60
predicted
80 percent
percent
percent
normal;
predicted;
predicted;
predicted;
FEV1/FVC
FEV1/FVC
FEV1/FVC
FEV1/FVC
normal
normal
reduced 5%
reduced 5%
Oral steroid use

0-1 per year

≥ 2 per year

≥ 2 per year

≥ 2 per year

Note. Asthma classification is based on symptom burden and lung function. Classification directs
appropriate treatment.
Treatment
Asthma management utilizes a step-down approach for treatment (Global Initiative for
Asthma, 2019). The Global Initiative for Asthma (GINA) published new guidelines for stepwise
treatment in June 2019, as seen in Table 2. For children ages six to eleven years old step one
consists of an as needed low dose inhaled corticoid steroid (ICS) in combination with a shortacting beta antagonist (SABA), or daily low dose ICS and as needed SABA (Global Initiative for
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Asthma, 2019). The next step, step two, is to increase to a daily low dose ICD or a leukotriene
receptor antagonist (LTRA) and SABA as needed (Global Initiative for Asthma, 2019). Step
three consists of a low dose ICS-long acting beta-agonist (LABA), or medium-dose ICS, or low
dose ICS and LTRA, along with SABA as needed (Global Initiative for Asthma, 2019). For
increased control, step four includes a medium-dose ICS-LABA or a high dose ICS-LABA or by
adding tiotropium. SABA should be used as needed for exacerbations (Global Initiative for
Asthma, 2019). The final step includes referring for a phenotypic assessment and additional addon therapies (Global Initiative for Asthma, 2019). These guidelines resemble previous guidelines
from GINA's 2008 report, however, guidelines for children 12 years and older have changed
concerning the rescue inhaler preference (Global Initiative for Asthma, 2019).
Table 2
Treatment Guidelines for Children 6-11 Years Old (Global Initiative for Asthma, 2019).
Treatment
Step 1
Step 2
Step 3
Step 4
Step 5
Preferred
controller

Other
controller
option

Reliever

Low dose
ICS as
needed with
SABA use, or
daily low
dose ICS

Daily low
dose ICS

Low dose
ICS-LABA
or medium
dose ICS

Medium dose
ICS-LABA
Refer for
expert advice

LTRA, or
low dose ICS
as needed
with SABA
use

Low dose
ICS + LTRA

High dose
ICS-LABA,
or add-on
tiotropium or
add-on
LTRA

SABA as needed

Refer for
phenotypic
assessment
May add on
additional
therapy
Add-on antiIL5, or addon low dose
OCS
(consider side
effects)

Note. 2019 GINA guidelines for asthma management.
For children and adolescents 12 years and older, a step-down approach continues to be
utilized for asthma management. Table 3 outlines this stepwise approach. Step one consists of an
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as needed low dose ICS-formoterol or a SABA as a recuse inhaler options (Global Initiative for
Asthma, 2019). Step two is a low dose ICS or LTRA, and an as needed ISC-formoterol (Global
Initiative for Asthma, 2019). Step three is a low dose of ICS-LABA or a medium-dose ICS or a
low dose ICS and LTRA, along with a low dose ICS-formoterol as needed (Global Initiative for
Asthma, 2019). Step four is stepping up to a medium dose ICS-LABA or a high dose ICS and
tiotropium or LTRA, along with a low dose ICS-formoterol (Global Initiative for Asthma, 2019).
Traditionally, a SABA has exclusively been used as a rescue inhaler, however, in the updated
guidelines a low dose ICS-LABA may replace the SABA during exacerbations (Global Initiative
for Asthma, 2019). In the role of acute exacerbations for both age groups, a SABA inhaler or
nebulization and oral steroids are beneficial.
Table 3
Treatment Guidelines for Adults and Children 12 Years Old and Older (Global Initiative for
Asthma, 2019).
Treatment
Step 1
Step 2
Step 3
Step 4
Step 5
Preferred
controller

As-needed
low dose
ICSformoterol

Low dose
ICS-LABA

Low dose
ICS-LABA

Other
controller
option

Low dose
ICS as
needed with
SABA use

Medium dose
ICS or
low dose
ICS+LTRA

Medium dose
ICS or
Low dose
ICS+LTRA

Reliever
Other reliever
option

ICS-formoterol as needed

Medium dose
ICS-LABA

High dose
ICS-LABA
Refer for
phenotypic
assessment
Consider
add-on
therapy
Add low dose
OCS, but
consider side
effects

High dose
ICS, add-on
tiotropium or
add-on
LTRA
Low dose ICS-formoterol for patient
prescribed maintenance and reliever therapy
as needed
SABA as needed

Note. 2019 GINA guidelines for asthma management.
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Individuals with a diagnosis of asthma are expected to fill out a control test at the
beginning of their appointment for state-wide reporting purposes (MN Community
Measurement, 2018). Children ages 12 years and older fill out a five question survey referred to
as the Asthma Control Test (ACT), which assesses their perceived level of asthma control
(Minnesota Department of Health, 2010a). Additionally, they are also asked to fill out the
number of emergency department (ED) visits and hospitalizations they have had in the past year
due to asthma (Minnesota Department of Health, 2010a). Children under the age of 12 fill out a
Childhood Asthma Control Test (CACT) with the assistance of a parent or guardian to assess
their control level. There are four questions on the CACT that are intended for the child to
answer as best as he or she can, while three questions are solely for the parent or guardian to
answer (Minnesota Department of Health, 2010b). The CACT also records the number of ED
visits and hospitalizations due to asthma in the past 12 months (Minnesota Department of Health,
2010b). A passing score for both the ACT and CACT is scoring above a 19 (Minnesota
Department of Health, 2010a).
Not only is this information reportable to the state, but it can also be used to guide
treatment (MN Community Measurement, 2018). In a study by Schatz et al. (2006), 313 patients
at an asthma specialty clinic had their ACT scores compared to their spirometry as well as their
provider’s rating of their asthma control. This study demonstrated that the ACT score was
reliable for assessing asthma control (Schatz et al., 2006). Therefore, these questionnaires
should be considered along with symptom burden and physical exam when considering the
appropriate treatment.
With the step-down method, providers may start asthma control higher than what may be
required for long term control. After two to three months of control, the level of management
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may be decreased until the child is on the lowest amount of medication required for optimum
control (Sawicki & Haver, 2018). Asthma is often managed through primary care providers,
however, there are circumstances when a referral to a pulmonologist or allergist is required. For
example, a referral may be made when the diagnosis of asthma is uncertain (Sawicki & Haver,
2018). Referrals may also be made when asthma is difficult to control or exacerbations
frequently occur (Sawicki & Haver, 2018). One other indication for referral to a specialist is
adverse effects from asthma medication (Sawicki & Haver, 2018). Although asthma is often
managed in family medicine, specialty care plays an integral role in pediatric asthma control.
Specialty care in pediatric asthma management often consists of a team of doctors,
nurses, physician assistants, nurse practitioners, and respiratory therapists (Fanta, 2017). In the
pediatric setting, the pediatricians overseeing specialty care clinics specialize in pulmonology or
immunology (Fanta, 2017). Many pediatricians working with the pediatric asthmatic population
receive fellowship training as well as advanced certification in the subspecialty of pediatric
pulmonology and allergy/immunology awarded by the American Board of Pediatrics (Althouse
& Stockman, 2016).
Asthma not only affects physical health but also can impact the social health of patients
and their families. Children who are diagnosed with asthma may develop anxiety surrounding
their disease or even the fear of dying (Sawicki & Haver, 2018). Asthmatic children’s social
health may be impacted as well with fears of being ostracized for being "different" (Sawicki &
Haver, 2018). Asthma may also impact children's performance in school. Nocturnal symptoms
may prevent individuals from sufficient sleep, leading to difficulty concentrating and difficulty
learning (Sawicki & Haver, 2018). Asthma is also associated with increased absenteeism. In a
study by Sullivan et al. (2017) a retrograde study looked at school-aged children with asthma and

32
compared them to those without. The findings revealed that children with asthma miss school
1.54 times more often than those without (Sullivan et al., 2017). Children with asthma were
found to have a lower level of physical activity in school (Williams, Hoskins, Pow, Neville,
Mukhopadhyay, & Coyle, 2010). In the study by Williams et al. (2010), it was demonstrated that
teachers often had difficulty differentiating inattentiveness due to asthma from lack of
motivation. Therefore, children with asthma were more likely to have limitations placed on their
participation (Williams et al., 2010).
Not only can a diagnosis of asthma have implications on the individuals themselves, but
also their families. Controller inhalers are often very expensive, even with insurance. This
diagnosis may become a financial burden on families (Sawicki & Haver, 2018). This may also
lead to restrictions on travel or social events that families attend (Sawicki & Haver, 2018). For
example, if a grandparent smokes families may avoid visiting the grandparent's home. Family
dynamics may also shift, with the primary focus on the individual with asthma. This may lead to
sibling resentment for special treatment (Sawicki & Haver, 2018). Although asthma physically
affects an individual's body, it is important to acknowledge that there are many other aspects of a
child's life that a diagnosis of asthma may affect.
MN Community Measurement
MN Community Measurement is a nonprofit organization that was created in 2005 (MN
Community Measurement, 2019). The mission of this organization is to create transparency and
accountability for healthcare in Minnesota (MN Community Measurement, 2019). This group’s
stakeholders are a diverse group of healthcare providers and insurance companies, as well as
patients and government employees (MN Community Measurement, 2019). In 2010, Minnesota
passed legislation that required the Minnesota Department of Health (MDH) to publish standards
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of care for quality control statewide ("Statewide programs," n.d.). With this law, every clinic and
hospital in Minnesota are required to report their patient outcomes for specific conditions, such
as asthma, annually ("Statewide programs," n.d.).
Clinics and hospitals may use MN Community Measurement’s data to compare amongst
surrounding practices and to improve quality of care (MN Community Measurement, 2019). Not
only can clinics compare themselves, but this data may be utilized as a tool for parents to
research and compare clinic’s asthma control rates (MN Community Measurement, n.d.). This
annual report also allows insurance companies and government programs to look at outcomes,
fueling the incentive for outcomes rather than volume reimbursement (MN Community
Measurement, 2019). The reporting processes can be cumbersome for clinics, therefore, MN
Community Measurement is working on improving this data collection process in hopes of
providing easily accessible and accurate information (MN Community Measurement, 2019).
Annually, clinics and hospitals are ranked on their asthma control utilizing both patientreported outcomes and performance measurements. Data is collected on statewide family
medicine, internal medicine, pediatric, allergy and immunology, and pulmonary practices (MN
Community Measurement, 2018). A reporting year includes the annual calendar year, during
which time if a patient ages 5-17 years old with a diagnosis of asthma is seen by an eligible
provider, then this patient must be reported for the clinic's denominator (MN Community
Measurement, 2018). Eligible providers include medical doctors, doctors of osteopathic
medicine, physician assistants, and advanced practice nurse practitioners (MN Community
Measurement, 2018). The total number of eligible patients is then compared to the number of
controlled patients to obtain the rate of optimally controlled asthmatics.
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The numerator is determined by the number of patients who meet the following two
criteria. The first criteria is passing the Asthma Control Test (ACT) for children ages 12 years
and older, and the Childhood Asthma Control Test (CACT) for children ages five to eleven years
old (MN Community Measurement, 2018). To pass the ACT or CACT, a patient must score a 20
or above. If neither of these tests are used, then the Asthma Therapy Assessment Questionnaire
(ATAQ) may be used. A patient must obtain a score of zero on the ATAQ to be considered wellcontrolled for ages 5-17 years old (MN Community Measurement, 2018). The second criteria
involves the risk of exacerbation. Patients must have reported less than two hospitalizations or
visits to the emergency department for asthma in the previous 12 months (MN Community
Measurement, 2018). If both of the criteria are met then a patient may be counted toward the
numerator. The greater the ratio the better control a practice has with their asthmatic population
(MN Community Measurement, 2018).
In the reporting process, there are some exclusions from a patient population perspective.
For patients with a concurrent diagnosis of cystic fibrosis, chronic obstructive pulmonary
disease, emphysema, or acute respiratory failure, these patients are excluded from the annual
reporting (MN Community Measurement, 2018). In addition, there are also allowable exclusions
including if the patient was in hospice, receiving palliative care, or in a permanent nursing home
at any time during the reporting period (MN Community Measurement, 2018). Patients who
have died before the measurement period was over or only had urgent care visits are also
excluded (MN Community Measurement, 2018). In the most recent published report, the
statewide average for optimally controlled asthma in children was 57.9% (MN Community
Measurement, 2019). Comparatively, the 90th percentile of medical groups in Minnesota had an
average ratio of 70.6% (MN Community Measurement, 2019). The range for medical groups
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individually ranged from 0% to 83.9% of optimal control (MN Community Measurement, 2019).
When compared to the national data from 2012-2014, on average half of children diagnosed with
asthma were considered well-controlled (Center for Disease Control and Prevention, 2017a).
Specialty Care in Pediatric Asthma
Specialty care plays an important role in pediatric asthma management. In a study
conducted in 2019, 149 children who presented to the emergency department for an asthma
exacerbation were surveyed. Of those patients, 20% were seen by specialists for their asthma
(Pade, Agnihotri, Vangala, Thompson, Wan, & Okelo, 2019). Of the population, three-fourths
met the criteria for a referral to a specialist (Pade et al., 2019). Around 80% of the parents who
were not seeing a specialist expressed interest in being followed by a specialist for their child’s
asthma management (Pade et al., 2019). This study demonstrated that the majority, 87%, of
parents who were not seeing a specialist were not doing so due to the "perceived lack of
necessity by their primary care provider" (Pade et al., 2019, p. 1). Another study by Agnihotri
(n.d.) looked at children who presented to the emergency department for asthma exacerbations
measuring the control of their asthma. This study demonstrated that there was a large population
of patients who either had ED visit, hospitalization, or an ICU admission for asthma who were
not managed by specialty care (Agnihotri, n.d.). The study also reported that only 1% of primary
care providers were using validated questionnaires to assess their patient’s asthma severity
(Agnihotri, n.d.). It was suggested that this reduction in questionnaire use may contribute to a
lack of recognition at the primary care provider level as to who should be managed by specialty
care. This study also demonstrated that parents were less likely to pursue specialty care if their
primary care provider did not recommend it (Agnihotri, n.d.). The findings of the study
conducted by Agnihotri (n.d.) support those concluded by Pade et al. (2019).
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Room for more documentation and exploration of the role of specialty care in pediatric
asthma management is needed. Within 10 miles of Minneapolis, there are 7 specialty clinics for
pediatric asthma (MN Community Measurement, n.d.). Asthma is a very common and
potentially life-threatening illness that affects many children. Specialty care, whether by a
pulmonologist or allergist, is an important step in controlling difficult or atypical asthma.
Conclusion
In summary, asthma is a common chronic illness that impacts 7.4% of children in
Minnesota (Centers for Disease Control and Prevention, 2019b). The diagnosis, treatment, and
management of this disease may require specialty care providers in order to provide optimal
control. The Pade et al. and Agnihotri studies discussed in this chapter, demonstrated a
correlation between patients who utilized specialty care management with a reduction in ED
visits and hospitalizations. The following chapter will describe the methodology used to analyze
the retrospective study of pediatric asthmatics managed by a specialty care clinic in Minnesota.
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Chapter 3: Methods
Introduction
The objective of this study was to assess the role of specialty care in pediatric asthma
management. Through the use of an in-depth chart review and analysis of pediatric patients at a
specific asthma specialty care clinic, this research addressed the following questions:
1. What are the most common referral sources leading to specialty consultation for pediatric
asthmatics management and control?
2. What is the role of specialty care management in pediatric asthma? Specifically, what
types of interventions, counseling, or treatments were offered to Minnesota patients at
this specialty care clinic from January 2018 through December 2018?
3. How does specialty care management influence or affect pediatric asthmatic outcomes?
The intent of Chapter 3: Methods was to provide a clear and precise understanding of the
research methodology used in the assessment of the gathered data. This examination reviewed
the study design and selected variables, the rationale for population selection criteria,
experimental procedures, and the data collection process.
Study Design
The study was designed to be a descriptive, quantitative, retrospective, cohort study. This
specific methodology was chosen as a means of producing an objective and thorough review of
the gathered data and to provide insight into the proposed research questions. The descriptive
research aimed to accurately describe the specific pediatric asthmatic population using the chart
review process. The collected data was quantitative and based on the selected clinical parameters
and numerical values such as PFT results. The research identified a specific cohort consisting of
pediatric patients treated at a specialty care clinic and involved a retrospective examination of
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patient records spanning from January 2018 through December 2018. Independent variables
included medications and visit count. Dependent variables consisted of PFT values. These
variables were used to describe the data and examine clinical outcomes identified through the
analysis of patient records.
Population
The research data was collected and analyzed from the medical records at Children's
Respiratory & Critical Care Specialists (CRCCS). This clinic provided quality health care in
pediatric pulmonology and critical care medicine with six locations throughout Minnesota. This
study's author was connected to this clinic through previous employment and received full access
to patient records to compile research data.
The participants of this study were children up to the age of 18 years old with the
diagnosis of asthma who were newly referred to CRCCS beginning January 2018 through
December 2018 for an initial consultation and who had at least one additional follow-up
appointment during that timeframe. These criteria were selected to specifically measure the
interventions that were put into place by the specialty care provider instead of those set by the
primary care provider before the initial consultation. The sample consisted of participants under
the age of 18 as the clinic does not manage adult asthmatics and the research intended to focus
specifically on pediatric patients. No other exclusion criteria was considered when selecting the
population. The participation goal was to gather clinic records from between 50-100 patients to
utilize for analysis purposes.
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Experimental Procedures/Protocol
Quantitative clinical outcomes were reviewed to determine if there was a correlation
between specialty care management and asthma control. Data was collected from CRCCS using
their electronic medical record, eClinicalWorks (eCW). Inside of eCW was a function that
allowed reports to be run on quantitative data. This function was called Enterprise Business
Optimizer (eBO). Using eBO, a data set was created. Information that was pulled from this
report included medical record number (MRN), date of service (DOS), ACT/CACT scores, ED
visits/hospitalizations, and steroid bursts. This report was generated for asthma patients who
presented to the clinic for the first time between January 2018 through December 2018, and who
also completed a follow-up clinic visit during that timeframe. Consent was obtained through a
general consent form updated annually seen in appendix A. The general consent form was
resigned annually by parental guardians authorizing the release of protected health information
for medical and scientific research purposes. Appendix B provided written consent to access
electronic medical record data from CRCCS.
A chart review was completed for changes in classes of medication as well as for the
source of referral. The classes of medications that were collected are included in Table 4. Dosing
changes were also be tracked. These changes were recorded in an excel spreadsheet organized by
class and potency of drugs.
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Table 4
Classification of Drugs (Allergy & Asthma Network, 2016)
ICS Low
Flovent HFA 44 mcg
QVAR HFA 40 mcg
Asmanex HFA 100 mcg
Budesonide Neb 0.5mg/2mL
ICS Medium
Flovent HFA 110 mcg
QVAR HFA 80 mcg
ICS High
Flovent HFA 250 mcg
Asmanex HFA 200 mcg
ICS-LABA Low
Advair HFA 45/21 mcg
Symbicort HFA 80/4.5 mcg
Dulera HFA 100 mcg
ICS-LABA Medium
Advair HFA 115/21 mcg
ICS-LABA High
Advair HFA 230/21 mcg
Symbicort 160/4.5 mcg
Dulera HFA 200 mcg
LTRA
Montelukast, Singulair
H1 anti-histamine
Cetirizine
Biologics
Xolair, Fasenra, Dupixent
Antibiotics
Alternate day Azithromycin
Steroids
Prednisone, Prednisolone, Dexamethasone,
Triamcinolone
Albuterol
Proair, Ventolin, Xopenex
Albuterol & Ipratropium
DuoNeb
The referral source was also chart reviewed. Categories that referrals were organized into
include referral from primary care provider (PCP), self-referral/friend or hospital follow-up. A
hospital follow-up meant that a patient who had not previously established care with CRCCS
was consulted by a pulmonologist while they were inpatient. At hospital discharge patients were
instructed to schedule a follow-up appointment with CRCCS within four weeks.
Participant’s protected health information (PHI) was protected by collecting de-identified
information outside of their MRN and DOS. While the MRN was protected health information,
this number was only used to correlate appointment and clinical outcomes to corresponding
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patients. MRNs were excluded in statistical analysis. The electronic data, while being collected
and analyzed, was kept on a password-protected computer owned by the researchers. After
completion of the study, the data will be kept on an external storage device locked in the PA
program office for a minimum of five years, per securing requirements for Bethel University's
Physician Assistant Program and deleted from the researcher’s computers.
Statistical Methods
Using the excel spreadsheet generated by eBO, descriptive statistics were used for PFT
values. The frequency of the intervention type and referral methods were recorded. Clinical
outcomes on the final visit were compared to those taken on the initial consultation utilizing a
paired T-test in order to examine any statistically significant changes in PFT values.
Referral sources and medication changes were analyzed as well using graphics. The
percentage of each referral source was displayed on a pie chart. This gave a visual representation
of where the majority of referrals to specialty care originated. Bar graphs were created to
compare medications at first appointment with changes made while under the management of
CRCCS. The bar graph allowed any trends in medication changes at a specialty care level to be
visualized.
Validity and Reliability
This study utilized previously established tools such as PFT values to evaluate clinical
outcomes. In a study conducted by Schatz et al., patient-reported ACT scores were compared to
PFT values and specialists ratings of the individual’s asthma control (Schatz et al., 2006). This
comparison demonstrated that ACT scoring is a reliable and valid tool for assessing asthma
control (Schatz et al., 2006).
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The National Asthma Education and Prevention Program recommended that PFTs be
measured at the time of initial evaluation and repeated frequently to provide an accurate
diagnosis and assessment of disease severity (Nair, Daigle, DeCuir, Lapin & Schramm, 2005).
Without completion of PFTs, providers were more likely to overestimate the degree of asthma
control leading to potential sub-optimal therapy and negative outcomes (Nair, Daigle, DeCuir,
Lapin & Schramm, 2005). Additionally, adherence to the guidelines concerning the use of PFTs
for asthmatic children was associated with a reduced risk of hospitalization (Moth, Schiotz,
Parner & Vedsted, 2010). The three key factors of obtaining a valid PFT measurement included
the use of accurate instrumentation, a patient capable of performing acceptable and repeatable
measurements, and a motivated clinician to elicit maximum performance effort (Ruppel &
Enright, 2012). In this way, PFTs were difficult to obtain in children younger than 5 years of age.
However, in the study conducted by Eigen et al, valid and reproducible PFT measurements
performed by trained pediatric pulmonary function technicians were greater than 80% of the 307
children between the ages of 3-6 years old (Eigen et al, 2001). For the purpose of this study,
CRCCS did not collect PFT measurements on children less than the age of 5 years old.
Limitations/Delimitations
This study was limited due to the inability to control for patient compliance with
treatment recommendations or availability of resources. Additionally, this study did not account
for the primary care management of pediatric patients before coming into the specialty care
clinic. Nor specifically, determined when a referral was discussed and the time in which the
patient chose or was able to come in for the initial assessment and how that timing may have
impacted outcomes. Another limitation requiring consideration was the availability of treatment
therapy recommendations and options during the predetermined timeframe of January 2018
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through December 2018. Recently, the 2019 GINA came out with new recommendations that
may be considered the most fundamental change in asthma management in 30 years (Reddel et
al., 2019). One of these new asthma management recommendations discouraged the oncestandard use of short-acting bronchodilators alone as needed, to now advising for the use of a
combination inhaler with a corticosteroid and long-acting bronchodilator for rescue inhalation
(Global Institute for Asthma, 2019).
As this study reviewed patient records before this change in guidelines, the treatment
strategies utilized at that time may not be what is currently recommended for pediatric asthmatic
control. As far as the delimitations of the research, this study was confined to the analysis of
chart reviews at one specific specialty care clinic in the Minnesota metro area. Additionally, the
charts reviewed spanned from a pre-determined timeframe from January 2018 through December
2018 and consisted of patients who have completed an initial consultation as well as a follow-up
appointment.
Conclusion
The purpose of this study sought to retrospectively analyze a specific pediatric asthma
specialty care clinic in Minnesota during January 2018 through December 2018 and identified
the most common referral sources, types of medication utilized, and subsequent patient
outcomes. This chapter described the intended pediatric patient population, the chosen specialty
care clinic, independent and dependent variables, and the experimental procedures and protocols
utilized to gather the data. The information collected from the patient chart reviews was analyzed
and presented in Chapter 4: Results. Chapter 5: Discussion reviewed the interpretation of the
results in relation to the identified research questions.
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Chapter 4: Results
Introduction
This study aimed to understand the role of specialty care in the pediatric asthmatic
population in the Twin Cities. A chart audit of 352 patient’s appointments from January 2018
through December 2018 was conducted. This audit acquired information regarding referral
sources, number of visits, medication changes, and PFT changes. Microsoft Excel was used for
the data analysis along with the XLSTAT Cloud application. Data was demonstrated via
graphical displays, such as graphs and tables.
Demographics
The demographic information included children up to the age of 18 years old with the
diagnosis of asthma. Of these children, they must have presented to the respiratory clinic as a
new patient during from January 2018 through December 2018 and returned for at least one
appointment during that same calendar year. 352 patients met these criteria and 924
appointments took place during the specified time frame. Data obtained from the qualifying
visits met the criteria per Chapter 3: Methods.
Data Analysis
The initial research question asked about the source of referrals leading to specialty care
consultation. Figure 4 illustrates the various patient referral sources. Of the 352 new patients,
25% of them became involved in specialty care due to an asthma exacerbation resulting in a
hospitalization (Figure 4). 8% of patients presented on their own accord, and most patients, 67%,
were referred by their primary care provider (Figure 4).
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Referral Source
27, 8%
89, 25%

235, 67%
HFU

PCP

Self/Friend

Figure 4. Referral source from the initial visit. HFU represents “hospital follow up”, PCP
represents “primary care provider”, and self/friend is anyone who is not a medical provider
directly involved in the patient’s care.
The second research question addressed the role of specialty care management in asthma
and the types of interventions used during patient visits. Upon chart review, during January 2018
through December 2018, there were 924 appointments. The frequency of visits in the calendar
year varied from two to seven visits (Figure 5). The subsequent figures summarize the
interventions utilized at each appointment depicting both current and initiated medications
(Figures 6-11). 76 patients were started on a SABA during the initial visit (Figure 6). By the
second visit, 348 out of 352 patients were on a rescue inhaler (Figure 7). 184 patients were
started on or had a controller inhaler changed during the initial visit (Figure 6). On the second
visit, 71 patients had a controller inhaler added or changed during the appointment (Figure 7).
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During the first visit, 181 patients had oral steroids added to their treatment regimen for
exacerbations (Figure 6).

Visit Count
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Figure 5. The number of visits per patient.
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Number of Patients

Initial Visit
350
300
250
200
150
100
50
0

288
181
32 62
21
31

12

43
5

47
33
16
14 1931 31
3
15
7

Current regimen

60 54

Started regimen

Figure 6. Medications summary after the initial appointment. 352 patients were included.
Current regimen indicates that the medications were “continued” or “refilled.” Started regimen
indicates that the medication was started at that visit.
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Number of Patients

Second Visit
400
350
300
250
200
150
100
50
0

345
236
80
65
12
12

31

59
50
37 19
38
28
19
12
20
11 16
6

Current Regimen

3

28

Started Regimen

Figure 7. Medications summary after the second appointment. 352 patients were included.
Current regimen indicates that the medications were “continued” or “refilled.” Started regimen
indicates that the medication was started at that visit.
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Number of Patients

Third Visit
160
140
120
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0
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1

1
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2
5

Current Regimen

34

26
11
1
2
2

1

24
10

9

Started Regimen

Figure 8. Medications summary after the third appointment. 145 patients were included. Current
regimen indicates that the medications were “continued” or “refilled.” Started regimen indicates
that the medication was started at that visit.
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Figure 9. Medications summary after the fourth appointment. 55 patients were included. Current
regimen indicates that the medications were “continued” or “refilled.” Started regimen indicates
that the medication was started at that visit.
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Number of Patients

Fifth Visit
14
12
10
8
6
4
2
0

7
3

1

1

2

1

Current Regimen

13
6

3

3

Started Regimen

Figure 10. Medications summary after the fifth appointment. 15 patients were included. Current
regimen indicates that the medications were “continued” or “refilled.” Started regimen indicates
that the medication was started at that visit.
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Number of Patients

Sixth Visit
3.5
3
2.5
2
1.5
1
0.5
0

3
2
1

1

Curent Regimen

1

11

Started Regimen

Figure 11. Medications summary after the fifth appointment. 4 patients were included. Current
regimen indicates that the medications were “continued” or “refilled.” Started regimen indicates
that the medication was started at that visit. There was only 1 patient with 7 visits. This patient
received refills for their ICS LABA High, SABA, and oral steroids.
The third research question investigated the role of specialty care in pediatric asthma
outcomes. 179 individual patients participated in PFT testing. The number of appointments
between the first and last appointment varied as well as the length of time between the first and
last appointment. 89 patients had one or more appointments between the first and last visit. The
average length between the first and last appointment was 145 days. From the original 352
patients, 165 patients were ineligible for PFT testing based on their age and 8 patients underwent
exercise challenge tests (ECT) instead of PFT testing. Therefore, 173 patients were excluded
from the analysis. When comparing the FEV1 of initial visits to FEV1 of last visits the p-value is
0.038, which is statistically significant.
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Table 5
PFT Analysis

Minimum (%)

Maximum (%)

Mean

Std. deviation

FEV1 of initial visit

31

141

90.429

18.649

FEV1 of last visit

47

136

94.206

16.566

Note. Sample size of 179 patients. P-value is 0.038, which is statistically significant.
Conclusion
A sample size of 352 patients was chart audited in order to understand further the role of
specialty care in the pediatric asthmatic population in Minnesota. The majority, 67%, of the
patients who presented to specialty care were referred by a PCP. Regarding medication changes,
52% of patients had modifications made to controller medications during the initial appointment.
There was also a statistically significant increase in FEV1 percentages when the initial visit and
the last visit were compared. The data found from the chart review is compared to previously
established literature and discussed further in Chapter 5: Discussion.
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Chapter 5: Discussion
Introduction
As pediatric asthma remains a prevalent, costly, and life-limiting disease, it is imperative
that medical providers be familiar with effective treatment options. Disease management may
require incorporating a pulmonary specialty care clinic with practitioners who are knowledgeable
of the most current treatment guidelines and interventions. The purpose of this study sought to
retrospectively analyze a specific pediatric asthma specialty care clinic in Minnesota during
January 2018 through December 2018 and identify the most common referral sources, types of
medication utilized, and subsequent patient outcomes. This final chapter provided conclusions
based on the purpose of the study, proposed research questions, and the corresponding findings
as recorded in Chapter 4: Results. Additionally, the included discussion addressed the limitations
encountered when gathering and analyzing the patient data as well as areas of future research to
which this study may contribute.
Summary of Results
When completing this study consisting of an in-depth chart review of a Minnesota-based
pediatric asthmatic clinic, the initial research question focused primarily on the referral sources
leading to specialty care consultation. As discussed in Chapter 2: Literature review, the parents
of pediatric asthmatics are typically interested in being followed by a specialty provider for
asthma management (Pade et al., 2019). Despite meeting the qualifying criteria for consultation,
patients may or may not be referred for specialty care management depending on the primary
care provider’s perceived clinical need and initiative (Pade et al., 2019). This finding correlated
well with our study results, which demonstrated that the most common referral source leading to
specialty care evaluation came from the patient’s primary care provider (67%). Other less
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common sources were seen in patients presenting after an acute asthma exacerbation leading to a
referral established as a part of the hospitalization discharge process (25%) or those stemming
from a self-referral made by parents on behalf of their child (8%). Together, the results of this
study, as well as those of the existing literature, could be used to support increased education of
primary care providers on the specialty care referral process, which could ultimately improve
patient satisfaction and disease management.
The second question inquired about the interventions utilized by specialty care. New
guidelines put forth in 2019 recommended that every patient diagnosed with asthma begin
treatment using a rescue inhaler, SABA, with the optional addition of using an ICS controller
inhaler (Global Initiative for Asthma, 2019). For the patients seen by specialty care, 17% of
individuals were started on a SABA (Figure 6). By the second visit, 99% of patients were on a
rescue inhaler (Figure 7). Therefore, specialty care management helped to ensure patients have
the proper tools for managing acute asthma attacks. During the first visit, changes to controller
medication were made in 52% patients either with the addition of a controller medication or
modifying the intensity of the controller medication to the appropriate level based on the clinical
picture and corresponding lab values (Figure 6). 27% of patients were started on either a chronic
antibiotic, LTRA, or an antihistamine during the first visit, adding additional coverage for
optimal control (Figure 6). Finally, rescue steroids were added to 51% of patient’s asthma
treatment plans at the initial visit (Figure 6). This addition allowed parents to have access to
another tool for managing asthma exacerbations at home with the hopes of decreasing ED visits
and hospital admissions.
The final research question investigated how clinical outcomes change during the course
of specialty management. FEV1 values helped to determine the amount of obstruction present in
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the lungs, with the higher percentages representing less obstruction and disease burden (Sawicki
& Haver, 2018). The average of FEV1 upon initial visit was 90% and improved up to an average
of 94% on the last visit of 2018 (Table 5). This change in value was statistically significant and
indicated that specialty care management effectively improved pediatric asthmatic care
outcomes. While there was no published source establishing the validity of specialty care
management, this study and others like it may one day contribute to solidifying its role as a
cornerstone for improving patient outcomes of the pediatric asthmatic population.
Limitations
As considered in Chapter 3: Methods, the anticipated study limitations arose in analyzing
the patient data collection and the inability to control for patient compliance of the recommended
treatment options when receiving specialty care management. Additionally, the study could not
account for the pediatric patients’ management before coming into the specialty care clinic or the
period of time in between appointments. The collected data did not indicate the specific visit type
for each session which also could contribute to result limitations. For example, a patient could
have been seen for a routine scheduled visit or could have presented as a “sick visit” during a
time of symptom exacerbation, likely leading to poor PFT value recordings.
Furthermore, the data did not incorporate demographic statistics such as gender, age, or
socioeconomic status; therefore, comparisons between those variables could not be concluded.
These unaccounted variables, in turn, may have impacted medication compliance or availability
of treatment options which could ultimately skew patient outcomes. Lastly, the study collected
patient data from patients seen in the specialty care clinic from January 2018 through December
2018. Since that time, new asthma management guidelines have been published which may no
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longer correspond with the recommended treatment strategies during the predetermined
timeframe.
Further Research
This study has contributed to understanding how one specialty care clinic influenced
pediatric asthmatic patient outcomes during January 2018 through December 2018. Further
research could feature other asthma clinics in various locations or gather patient data over a
longer timeframe than was used in this study. Ideally, future studies could incorporate the most
recent asthma management guidelines when analyzing patient data and corresponding outcomes.
Other areas of research could include analyzing emergency department visits and hospitalization
rates while being managed by specialty care.
Conclusion
The purpose of this retrospective cohort study was to review patient healthcare records
and explore the impact of specialty care consultation for pediatric asthmatic management.
Primary care providers will ultimately benefit from this research and that of the previously
established literature. There was a direct correlation between families desiring to be evaluated by
specialty care providers and the most common referral source stemming from the general
practitioner’s encouragement. This study contributed to the knowledge and understanding of the
various interventions seen in pediatric asthmatic management. Specialty care providers are
informed of the most recent diagnostic and treatment guidelines and incorporate the most
effective medication regimens for optimal asthma control. This knowledge, in turn, has the
potential to decrease acute asthma exacerbations, thereby reducing ED visits and
hospitalizations. Lastly, the results of this study suggested a statistically significant improvement
in patient outcomes when under specialty care services. While pediatric asthma remains a
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potentially challenging illness to treat, this study sought to illustrate the impact of specialty care
management on patient outcomes representing an overall improved quality of life. Hopefully,
providers and patient families alike can use this research to live happier, feel healthier, and
breathe easier.
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